BioMarin Pharmaceutical Stock Forecast for 2023 - 2025 - 2030
Updated on 05/07/2024
BioMarin Pharmaceutical Stock Forecast and Price Target
BioMarin Pharmaceutical has an average price target of $110.00 recently offered by five notable experts for 2024, which would represent a potential upside of approximately 33.2% from the last closing price in May, 2024 if reached. This potential increase is based on a high estimate of $140.00 and a low estimate of $80.00. If you are interested in BMRN stock, you should also look at its competitors.
33.20% Upside
BioMarin Pharmaceutical Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, BioMarin Pharmaceutical's Price has seen a drop from $105.04 to $0.00 – a 100.00% decrease. In the next year, analysts believe that Fair Value will reach $365.37 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NOVO B Stock Forecast | Novo Nordisk A/S | Outperform |
12
|
kr882.60 | Buy/Sell | kr696.07 | 8.77% |
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$27.77 | Buy/Sell | $32.87 | 9.83% |
| SAN Stock Forecast | Sanofi | Outperform |
16
|
91.88€ | Buy/Sell | 102.80€ | 18.63% |
| CSL Stock Forecast | CSL | Outperform |
12
|
$279.56 | Buy/Sell | $205.51 | -27.33% |
| 4568 Stock Forecast | Daiichi Sankyo Company | Buy |
4
|
¥5.32k | Buy/Sell | ¥5.24k | 8.94% |
BioMarin Pharmaceutical Revenue Forecast for 2023 - 2025 - 2030
In the last three years, BioMarin Pharmaceutical's Revenue has grown, rising from $1.86B to $2.42B – a growth of 30.03%. In the next year, analysts believe that Revenue will reach $3.11B – an increase of 28.64%. For the next seven years, the forecast is for Revenue to grow by 136.96%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MRNA Stock Forecast | Moderna | Outperform |
16
|
$121.07 | Buy/Sell | $135.42 | 4.40% |
| 4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
5
|
¥4.10k | Buy/Sell | ¥4.74k | 11.00% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$218.92 | Buy/Sell | $299.62 | 31.78% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAYN Stock Forecast | Bayer | Hold |
5
|
28.49€ | Buy/Sell | 45.15€ | 5.30% |
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$154.33 | Buy/Sell | $245.24 | 40.93% |
| SRPT Stock Forecast | Sarepta Therapeutics | Outperform |
6
|
$136.04 | Buy/Sell | $158.66 | 21.66% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SOBI Stock Forecast | Swedish Orphan Biovitrum AB (p... | Outperform |
16
|
kr280.80 | Buy/Sell | kr293.00 | 15.74% |
| IONS Stock Forecast | Ionis Pharmaceuticals | Outperform |
9
|
$40.93 | Buy/Sell | $55.60 | 46.59% |
| GRF Stock Forecast | Grifols | Outperform |
18
|
9.29€ | Buy/Sell | 18.48€ | 102.37% |
BioMarin Pharmaceutical EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, BioMarin Pharmaceutical's EBITDA has grown by 1961.74%, rising from $13.41M to $276.48M. For the next year, analysts predict that EBITDA will reach $1.16B – an increase of 319.71%. Over the next seven years, experts believe that BioMarin Pharmaceutical's EBITDA will grow at a rate of 643.27%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DYN Stock Forecast | Dyne Therapeutics | Buy |
5
|
$25.65 | Buy/Sell | $28.13 | 42.30% |
| DCPH Stock Forecast | Deciphera Pharmaceuticals | Outperform |
6
|
$25.38 | Buy/Sell | $23.40 | 0.87% |
| NTLA Stock Forecast | Intellia Therapeutics | Outperform |
8
|
$23.88 | Buy/Sell | $75.84 | 193.13% |
BioMarin Pharmaceutical EBIT Forecast for 2023 - 2025 - 2030
In the last three years, BioMarin Pharmaceutical's EBIT has grown, moving from $-91.76M to $172.10M – an increase of 287.55%. In the next year, analysts predict that EBIT will jump to $810.76M – up 371.10% from the current level. Looking ahead to seven years, experts forecast that EBIT will grow by 1318.40%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4516 Stock Forecast | Nippon Shinyaku | Outperform |
18
|
¥4.39k | Buy/Sell | ¥8.34k | 48.20% |
| BCRX Stock Forecast | BioCryst Pharmaceuticals | Outperform |
7
|
$5.26 | Buy/Sell | $14.09 | 109.13% |
| PHARM Stock Forecast | Pharming Group N.V. | Buy |
16
|
0.90€ | Buy/Sell | 1.85€ | 127.78% |
BioMarin Pharmaceutical EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, BioMarin Pharmaceutical's EPS has seen a drop from $1.63 to $0.00 – a 100.00% decrease. In the next year, analysts believe that EPS will reach $5.67 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| WVE Stock Forecast | Wave Life Sciences | Outperform |
6
|
$5.79 | Buy/Sell | $9.21 | 133.16% |
| STOK Stock Forecast | Stoke Therapeutics | Buy |
4
|
$11.94 | Buy/Sell | $19.33 | 67.50% |
| ABUS Stock Forecast | Arbutus Biopharma | Outperform |
9
|
$2.84 | Buy/Sell | $6.34 | 92.96% |
Site Navigation
.jpg)